Clinical Trials Directory

Trials / Completed

CompletedNCT01261598

Predictive Value of FDG-TEP During Radiotherapy or Chemo-radiotherapy in Patients With NCSC on the One-year Survival

Predictive Value of FDG-TEP During Radiotherapy (RT) or Chemo-radiotherapy (CRT) in Patients With Non Small Cell Lung Cancer on the One-year Survival

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
98 (actual)
Sponsor
Centre Henri Becquerel · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The poor prognosis in the early-stage of lung cancer is due to potential worsening of the disease (local relapse, metastasis), to insufficient efficacy and toxicity of actual treatments. FDG-PET is a medical imaging modality allowing the quantification of the tumour glucose consumption. Then, this exam is used for pathology staging, target volume definition for RT, and treatment efficiency few months after RT or CRT. Our assumption is that an FDG-PET exam during the course of the RT or CRT might be predictive of the treatment efficiency few months later. In this study, the investigators propose to perform 4 FDG-PET: first "PET1" before radiotherapy, second "PET2" during the radiotherapy (see RTEP1), third and fourth "PET3" "PET4" 3month and 12 month after the therapy. The investigators will investigate the performances of FDG-PET performed during the RT or CRT for the prediction of the one-year patient heath outcome. If the predictive value of TEP2 is confirmed, the investigators would be able to optimize the planning treatment during the course of the therapy.

Conditions

Interventions

TypeNameDescription
PROCEDUREPositron Emission TomographyPositron Emission Tomography

Timeline

Start date
2007-11-01
Primary completion
2013-12-01
Completion
2013-12-01
First posted
2010-12-16
Last updated
2016-10-17

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT01261598. Inclusion in this directory is not an endorsement.